In atopic dermatitis, IL-13 and IL-4 produced by Th2 cells are known to promote the pathology, and monoclonal antibody preparations targeting IL-13/IL-4 receptors have become common treatments for atopic dermatitis [7]. Here, IL4 is linked to atopic eczema.